Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection-Reference-Cited by-同舟云学术

Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection

Published:2019-03 Issue:3 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Wasserman Sean¹^ORCID,Denti Paolo²^ORCID,Brust James C. M.³⁴,Abdelwahab Mahmoud²,Hlungulu Siphokazi¹,Wiesner Lubbe²^ORCID,Norman Jennifer²,Sirgel Frederick A.⁵,Warren Robin M.⁵,Esmail Aliasgar⁶,Dheda Keertan⁶,Gandhi Neel R.⁷⁸⁹,Meintjes Graeme¹,Maartens Gary¹²

Affiliation:

1. Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa

2. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

3. Division of General Internal Medicine, Albert Einstein College of Medicine, New York, New York, USA

4. Division of Infectious Diseases, Albert Einstein College of Medicine, New York, New York, USA

5. DST-NRF Centre of Excellence for Biomedical Tuberculosis Research/South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa

6. Lung Infection and Immunity Unit, Department of Medicine, University of Cape Town, Cape Town, South Africa

7. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

8. Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

9. Department of Medicine (Infectious Diseases), Emory School of Medicine, Emory University, Atlanta, Georgia, USA

Abstract

The World Health Organization (WHO) recently recommended that linezolid be prioritized in treatment regimens for drug-resistant tuberculosis (TB), but there are limited data on its pharmacokinetics (PK) in patients with this disease. We conducted an observational study to explore covariate effects on linezolid PK and to estimate the probability of PK/pharmacodynamic target attainment in South African patients with drug-resistant TB.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Wellcome Trust

European and Developing Countries Clinical Trials Partnership

National Research Foundation

South African Medical Research Council

MOHESR | National Research Foundation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02164-18

Reference33 articles.

1. World Health Organization. 2018. Global tuberculosis report 2018. World Health Organization, Geneva, Switzerland.

2. Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis

3. World Health Organization. 2018. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). World Health Organization, Geneva, Switzerland.

4. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multidrug-resistant tuberculosis;Nature Reviews Disease Primers;2024-03-24

2. A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides;2023-11-16

3. Recent advances in the treatment of tuberculosis;Clinical Microbiology and Infection;2023-07

4. Long-Term Intake of Linezolid Elevates Drug Exposure and Reduces Drug Clearance and Elimination in Adults With Drug-Resistant Pulmonary Tuberculosis;Therapeutic Drug Monitoring;2023-06-05

5. Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial;Clinical Infectious Diseases;2023-02-21